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Abstract: 
 
Human embryonic stem cells (hESCs) and hESC-derived cells are of great 
interest, not only because of their therapeutic potential, but also their 
prospective uses in in vitro drug and toxicity screening.  The ability to 
preserve these cells is critical, allowing for the generation of quality controlled 
stocks of cells, transport of cells between sites and avoiding the need for 
expensive and time consuming continuous culture.  Current methodologies, 
namely conventional slow freezing and vitrification, can successfully preserve 
hESCs and their differentiated progeny, retaining the key characteristics of the 
cells.  However, there is a significant gap between the number of cells 
potentially needed to either treat patients or run a high-throughput drug 
screen and how many cells can be preserved using these techniques.  
Therefore, this review focuses on the scalability of slow freezing and 
vitrification, identifying key barriers to success and whether they can be 
overcome.  Given the precedent with other mammalian cells in using slow 
freezing to successfully preserve large quantities of cells, and its compatibility 
with current and emerging culture methods for hESCs, it is likely to become 
the method of choice for cryopreserving these cells at scale.  However, issues 
other than scale still exist, therefore alternatives to cryopreservation should 
also be explored.  Here, the potential to lyophilise hESCs for long-term 
storage is considered as one such alternative.     
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1. Introduction 
 
Human embryonic stem cells (hESCs) hold great promise in the field of 
regenerative medicine.  These cells have the ability to self-renew and are 
pluripotent, meaning that, given the right stimulus, they have the ability to 
differentiate into almost any cell type of the body, such as cardiomyocytes, 
pancreatic β-cells, hepatocytes or neurons.  The potential of such hESC-
derived cells as therapeutic agents has recently been highlighted by the start 
of some long-awaited clinical trials in both the UK and USA. 1  Human ESCs 
and hESC-derived cells are also of great interest for the in vitro study of: 
development, genetic disorders 2 and use in drug discovery or toxicology 
studies. 3,4  For example, a high-throughput screen (HTS) was recently used 
to identify compounds that regulate hESC self-renewal and differentiation, 5 
supporting the use of these cells in HTS assays.  In another study it was 
found that hESC-derived cardiomyocytes can accurately indicate some 
adverse drug effects. 6  This suggests that if further developed, such systems 
could be used in drug safety testing as well as initial drug screening, 
potentially cutting down on the need for some animal testing.   Indeed, hESC-
derived cardiomyocytes for in vitro assays can now be purchased from a 
commercial source.  
 
Human ESCs are dependent on attachment to a matrix, provided by either a 
feeder layer of cells or an extracellular matrix substitute, for growth.    
Typically, they are grown as colonies in planar culture, although growth in 
monolayer culture can also be achieved.7-10  It has been estimated that 109 
cardiomyocytes are needed to repair a single infarcted heart, 11 but given the 
current inefficiency of both differentiation and separation protocols, the 
number of hESCs needed is likely to be closer to 1013.  Thus, in order to meet 
the potential demand for these cells, much of the current hESC research is 
focused on developing defined and scalable culture methods as well as 
directing differentiation in order to generate relevant cell types.  However, it is 
also important to consider how, once produced, both hESCs and their derived 
products will be preserved at scale.   
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As discussed in more detail in Section 2, preservation of these cells is critical 
to storing high quality stocks for either clinical or in vitro applications.  Figure 1 
shows that cells can be preserved at different points along the manufacturing 
process.  The most widely used technique for long-term preservation of 
mammalian cells is cryopreservation, with cells stored directly in liquid 
nitrogen (-196°C) or its vapour phase (-150°C).  Human ESCs or their 
differentiated progeny are frequently cryopreserved by conventional slow 
freezing methods, adapted from protocols used for mouse ESCs and other 
mammalian cells.  Slow freezing methods can allow the preservation of cells 
in a range of containers from 1 ml vials to 50-100 ml bags.  In contrast, 
vitrification, a rapid freezing method widely used for preservation of embryos, 
has also been used to preserve hESC colonies 12 but is generally conducted 
at a much smaller scale.  The so-called open pulled straw (OPS) method is 
most commonly used where clumps of hESCs in 1-20 μl of medium are stored 
in specialised cryostraws. 12   
 
Although the numbers of cells/dose needed is disease-dependent, 106-109 
cells are typically required per patient, 13 with disease prevalence further 
determining the total number of cells required per year.  Similarly, at the 
current seeding densities used, approximately 6x109 cells would need to be 
plated in order to screen a library of 1 million compounds in a HTS campaign. 
5  Even assuming 100% of cells are recovered post-preservation, which is 
often not the case, using current methodologies appreciably fewer cells can 
be cryopreserved.  This means that some cell culture is required between 
thawing cells and using them in therapy or HTS campaigns which is not ideal.  
For instance, one study stored up to 3x106 hESCs/cryostraw using a slow-
freezing protocol 14 and significantly fewer hESCs can be preserved by 
vitrification, although exact numbers can be difficult to ascertain.  Human 
ESCs are vitrified in clumps and, even when the numbers of cells/clump are 
determined, this can vary considerably from 100 to 400. 15,16  This makes the 
literature difficult to compare and presents an obvious disadvantage from a 
bioprocessing perspective because process monitoring and scheduling 
require accurate and consistent outputs.  Nonetheless, even using bulk 
methods, Li and colleagues 17 could only preserve ~120 clumps of cells per 
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cryocontainer, which assuming 400 cells/clump would be <5x104 
cells/cryocontainer.    
 
Given the current gap between the numbers of cells required and the capacity 
of current technologies to preserve hESCs and hESC-derived cells, the focus 
of this review is the scalability of conventional slow freezing and vitrification.  
Key barriers which limit the potential for either scale-up or scale-out of these 
methods are identified and discussed.  Furthermore, as scalability is not the 
only issue that should be considered when choosing a preservation 
technique, the suitability of lyophilisation to preserve hESCs and their 
differentiated progeny is also explored.   
 
 
2. Why preserve hESCs and their differentiated progeny? 
 
Human ESCs and hESC-derived cells are preserved for a number of different 
reasons.  Firstly, preservation allows for transport of cells between or across 
sites.  This is critical for storage and distribution facilities such as national 
stem cell banks and companies with multiple research or manufacturing sites.   
In addition, it also allows manufacturers of cellular therapies to develop 
business models where the production is spatially and temporally removed 
from the clinic.   
 
Secondly, preservation also allows the generation of master and working cell 
banks such that consistent, quality-controlled (QC), stocks of cells are 
available for in vitro studies and/or clinical use.  For instance, it has been 
estimated that approximately 150 hESC lines would be required to achieve a 
sufficient degree of human leukocyte antigen matching to be of benefit to the 
population, 18 although this number may be an underestimate. 19  To 
continuously culture such a large range of cell lines would be extremely 
expensive and time consuming.  Banking of hESCs is particularly important, 
as long term continuous culture has been associated with genetic and 
epigenetic instability. 19      
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Thirdly, preservation allows for the uncoupling of cell culture from other 
processes such as differentiation or delivery to patients.  Current 
differentiation protocols are typically complex, lengthy and expensive, 
therefore, preserving stocks of hESCs allows time for QC testing. This 
ensures that only high quality, well-characterised hESCs are taken forward 
through differentiation, thereby reducing waste and process inefficiency.  
Similarly, it allows for QC and safety testing before cells are delivered to 
patients and the development of an “off the shelf” business model for these 
therapies.  It also uncouples cell culture from in vitro cell-based assays, such 
as those used in toxicology studies.  In recent years there has been a surge in 
the use of freshly thawed cells for HTS assays, negating the need for 
continuous culture of cell lines and thereby cutting down on associated costs 
and lost time and effort when either cells, equipment or compounds are not 
ready simultaneously. 20,21 
 
 
3. Current Cryopreservation Methods 
 
Any preservation technology aims to reliably and consistently maintain the key 
characteristics of cells.  These include; viability, genotype, phenotype and, in 
the case of hESCs, differentiation potential.  An ideal method would be: widely 
applicable to a range of hESC lines and differentiated cells, scalable such that 
sufficient cells/container and enough containers/run can be preserved, and 
generate an output that is easily stored and transported.  Working with 
clinically relevant cells also adds the additional complexity that the process 
must be compliant with current Good Manufacturing Practice (GMP) 
guidelines, which limits or avoids the use of xenogeneic components and the 
use of chemical components which may cause adverse reactions in patients.   
 
As already mentioned, cryopreservation is the most widely used preservation 
method for mammalian cells, including hESCs and hESC-derived cells.  The 
dangers associated with freezing cells include intracellular ice crystal 
nucleation and osmotic stresses (depicted in Figure 2), which can result in a 
loss of cell viability and/or affect cell function. 22-25 Indeed, ideally the 
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formation of intracellular ice should be avoided and intracellular vitrification 
encouraged. 23  Therefore, two different freezing methods have been 
developed which aim to overcome these hurdles through the use of specific 
freezing rates and cryoprotective agents (CPAs): conventional slow freezing, 
in which the extracellular solution is frozen but the formation of intracellular ice 
is minimised, and vitrification, in which the formation of any ice crystals is 
avoided.  These methods are briefly outlined in Figure 3 (for in-depth reviews 
on aspects of cryobiology, including the role of CPAs and manual ice seeding, 
please refer to 22-26).  In all cases of cryopreservation, cells are recovered by 
means of a rapid thaw to reduce the risk of developing damaging ice crystals 
during thawing. 
 
 
3.1 Vitrification 
 
Vitrification is a method by which clumps of cells are placed in a 
cryoprotective medium and rapidly cooled by plunging samples into liquid 
nitrogen so that both extracellular and intracellular ice formation is avoided.  
The glass-phase transition temperature of water is -138°C and vitrification of 
pure water can only take place at a cooling rate of 106°C/sec or above. 22  
Therefore, in order to achieve vitrification of cell clumps at more modest rates, 
thermal mass is minimised and high concentrations of CPAs (~4M) are used. 
27  The presence of high concentrations of CPAs act to increase the viscosity, 
decrease rate of nucleation and ice crystal growth and increase the glass-
phase transition temperature of the solution such that vitrification can occur at 
achievable cooling rates. 22,25 
 
Although successfully used to preserve embryos 28 and hESCs (Section 3.2), 
vitrification does have its disadvantages.  Because rapid cooling rates must 
be achieved, only small volumes, typically 1-20 μl, may be vitrified, making 
this an extremely low-throughput process.  The high concentrations of CPAs 
(~4M), such as dimethylsulfoxide (DMSO), ethylene glycol and 1,2-
propanediol,  used to achieve vitrification can also be highly toxic. 27,29  
Furthermore, CPAs require a step-wise loading protocol 29,30 to avoid 
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exposing the cells to osmotic imbalances, making protocols very labour 
intensive.   
 
Vitrification protocols which use lower concentrations of CPAs are, however, 
being developed.  Cryostraws or loops are commonly used to vitrify cells and 
cooling rates of only ~20,000°C/min can be achieved, 31 necessitating the use 
of high concentrations of CPAs.  Recently, the use of quartz microcapillaries 
has enabled higher cooling rates (> 100,000°C/min) to be achieved and 
relatively low concentrations of CPAs (2M 1,2-propandiol and 0.5M trehalose) 
to be used in the preservation of mouse ESCs. 27  Furthermore, the use of 
quartz microcapillaries in combination with cell encapsulation technology, has 
also enabled the vitrification of mouse mesenchymal stromal cells in even 
lower concentrations of DMSO (~1.5M). 32  Although this does reduce 
exposure of cells to toxic agents, the need to use small volumes and/or a 
large surface area remains an absolute requirement in order to enable 
vitrification at easily achievable cooling rates.  Therefore, the potential to scale 
up the process is still very limited.  As will be mentioned in Section 3.2, some 
“bulk” vitrification methods have been developed through modification of 
cryocontainers, 17,33 but even these are limited in the numbers of cells that can 
be preserved per container.    
 
Instead, the development of protocols that require less manual input would 
allow for some scale-out of the process and vitrification of larger numbers of 
cells.  One such process is cell encapsulating droplet vitrification whereby 
cells are encapsulated in small droplets of CPA and injected directly into liquid 
nitrogen.  Tested on a range of mammalian cell types, this method allowed 
vitrification to occur in relatively low concentrations of CPAs (1.5M 
propanediol and 0.5M trehalose). 34  Although multiple step CPA loading and 
unloading processes were still used, the set-up used could potentially be 
automated, making it an attractive option for larger scale vitrification of cells.   
 
 
3.2 Vitrification of hESCs 
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Human ESCs grown in colonies, as opposed to monolayers, have typically 
been vitrified using an OPS technique as outlined in Figure 4.  High levels of 
cell recovery (>75%) have been recorded using this protocol, particularly 
when compared with some of the early attempts at preserving hESCs using 
slow freezing, 15,16,35 making this a popular choice.  In addition, in order to 
overcome the issues of sterility in such an open system and make it more 
GMP compatible, closed vitrification protocols have been developed. 16       
 
Although vitrified hESCs retain their ability to grow as colonies and 
differentiate upon thawing, the major drawback of using this method is the 
small number of cells that can be preserved per cryocontainer.  For example, 
Li et al vitrified 5-7 clumps, each containing 100-200 cells, per cryostraw, 
giving a maximum of 1400 cell per straw. 15  As mentioned in Section 3.1, the 
development of simpler, less labour intensive and time consuming protocols 
may allow for the vitrification of larger numbers of cells per run.  One such 
protocol involves the enzymatic dissociation of hESC colonies into clumps, 
transfer of cells into a single vitrification medium, and further transfer of the 
cells into a cryovial which is then immediately plunged into liquid nitrogen.  
Unfortunately, poor recovery rates of only 12% 36 and ~20% 37 currently make 
this method nonviable without a great deal of optimisation.   
 
More recently, a cell strainer has been used to vitrify hESCs colonies as this 
could hold a large number of clumps at once whilst retaining a rapid cooling 
rate once plunged into liquid nitrogen. 33  Although cells were successfully 
preserved, with high survival rates and retention of pluripotency, this new 
carrier was bulky and irregular in shape making it hard to manipulate and 
store.  Since then, Li and colleagues have devised an alternative 
cryocontainer, which is based on a 1 ml cryovial modified to contain a cell 
strainer, to overcome this. 17  Using this modified vial these workers were able 
to preserve 20 times more hESC clumps per straw than in the OPS method.  
Nonetheless, assuming a maximum of 400 cells/clump (based on numbers in 
16), this amounts to <5x104 cells/cryocontainer, compared to the 9x106 cells 
required for a HTS campaign. 5  Furthermore, the system currently requires ‘in 
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house’ adaptation of a commercially available cryovial which is not ideal from 
a bioprocess perspective.     
 
It is clear that even these so-called “bulk” or simplified methods are unable to 
preserve significant numbers of cells successfully and that they are not a true 
scale-up solution.  Similarly, even if the process could be automated, there 
still remains the issue of small numbers of cells per cryocontainer.  This would 
entail thawing numerous containers for any single application which is again 
labour intensive, and the need to maintain discrete batches for particular 
applications could lead to a significant amount of waste if batch size is not 
carefully controlled.  Thus, it remains questionable whether enough hESCs 
could ever be vitrified successfully to be used in cell therapies or in in vitro 
assays without the need for some culturing post-thaw.   
 
It is also notable that vitrification of hESCs has so far focussed on preserving 
fragments or clumps of hESC colonies.  The preservation and culture of cells 
in colonies is incompatible with general bioprocessing requirements due to 
their inherent heterogeneity and variability in size.  Human ESC propagation 
in monolayer, rather than colony culture facilitates cell processing and is 
therefore likely to become the standard for hESCs unless suspension or 
microcarrier culture can be achieved at a suitable scale.  Hence it is 
paramount that preservation strategies are compatible with this type of 
culture, where cells are enzymatically dissociated to single cells or small 
clumps of 2-3 cells.  To the author’s best knowledge, vitrification of suspended 
hESCs has not yet been reported.  However, methods such as the 
encapsulating droplet vitrification technique mentioned in Section 3.1, 34 which 
has been demonstrated to preserve post-thaw viability of mouse ESCs, show 
promise if they can be made GMP compatible. 
 
 
3.3 Conventional slow freezing 
 
Conventional slow freezing, or controlled-rate freezing, involves cooling the 
cells at approximately 1°C/min, most commonly in 1 ml polypropylene 
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cryovials, in a cryoprotective medium containing foetal bovine serum (FBS) 
and/or growth medium in addition to a CPA  (typically 5-10% v/v).  It is 
noteworthy that, reflecting the general trend within biopharmaceutical 
industries, commercial cryopreservation media are now available which do not 
include FBS.  This strategy enables the same level of protection for the cells, 
without the associated risks of using FBS, such as the potential for 
contamination with a transmissible spongiform encephalopathy and lot-lot 
variability.  Although every cell type, due to differences in membrane 
permeability, surface area and water content, potentially has a different ideal 
cooling rate, 22,24 1°C/min is generally appropriate and can be achieved in a 
low-tech fashion using a freezing container (e.g. “Mr. Frosty” manufactured by 
Nalgene) or using a controlled-rate freezer.  Prior to cooling (Fig. 3), ice 
nucleation should be deliberately initiated such that extracellular ice formation 
can occur in a controlled manner, particularly when preserving stress 
sensitive cells.   
 
A number of different compounds can serve as CPAs in slow freezing, 
including sugars such as trehalose and sucrose, but DMSO is the most widely 
used one.  In this method, CPAs that can penetrate the cell (e.g. DMSO) are 
used to reduce the freezing point of the intracellular solution and cell 
shrinkage, such that the desired intracellular vitrification can be achieved 
before intracellular ice forms. 22,23   Although relatively low concentrations of 
CPAs are used (typically <1.5M), most, including DMSO, are still toxic to cells, 
particularly at temperatures above 0°C 23,30 and thus exposure at room 
temperature must be limited.  This is achieved by rapidly commencing the 
freezing process before preservation and diluting out the CPAs from the cell 
mixture upon thawing.  Step-wise loading protocols can also be used to 
minimise osmotic shock to the cells.        
 
On a laboratory scale, 1-10x106 cells in 1 ml of cryopreservation medium in a 
1-2 ml polypropylene cryovial are commonly frozen and stored using the slow 
freezing method. 38  In order to cryopreserve larger quantities of cells, scale-
out methods could be considered.  For instance, automation of vial filling and 
capping, using systems such as the “Fill-It” (TAP Biosystems, Royston, UK) 
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can be used to increase the quantities of vials prepared, whilst ensuring cells 
are not exposed to potentially toxic CPAs for an extended period of time.    
 
Alternatively, a scale-up approach could be used by increasing the density of 
cells/ml frozen and/or increasing the size of cryocontainer.  However, this 
strategy would represent particular technical challenges. These include 
ensuring sufficiently high rates of heat transfer from the larger liquid volumes 
and high mass transfer of CPAs into the larger cell numbers.  One option is to 
use cryobags rather than large vials.  Typically used for blood banking, these 
have a large surface to volume ratio and therefore facilitate the removal of 
latent heat from the cells during the cooling process, making them more 
suitable for larger scale freezing than vials.  Indeed, studies have shown that 
significantly more than 106 cells at a time can be frozen by slow freezing 
methods using such bags.  For example, 50-100 ml of 20-50x106 Chinese 
Hamster Ovary (CHO)-S cells/ml were successfully cryopreserved in 250 ml 
bags. 38,39  However, cryobags have been known to fail 40 and it is important to 
consider the logistics of generating cell banks or doses of cellular therapies 
using these.  In one study 17x106 Baby Hamster Kidney (BHK) cells/ml were 
successfully preserved in 100 ml cryobags using a peristaltic pump to fill the 
bags at 100 ml/min and it was found that a 1.5 hour window existed in which 
to bank cells, using DMSO as a CPA. 41  Furthermore, bag handling can also 
be automated using systems such as the BioArchive ® System 
(ThermoGenesis Corp, CA, USA), indicating that using such bags for scale up 
of the slow freezing process is now possible.   
 
 
3.4  Conventional slow freezing of hESCs  
 
Although mouse ESCs can be successfully preserved by slow freezing, 
several studies have shown poor survival and recovery rates of hESC 
colonies or clumps when frozen using this protocol, quoting rates between 0-
30%. 12,15,16,42  For instance, in a comparative study, Li and colleagues 15 
found that no hESC clumps preserved by conventional slow freezing 
recovered post-thaw whereas 89% of vitrified cells did.  Clumps of cells 
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preserved in this manner are typically >70 μm in diameter  15 and recently, it 
was suggested that the poor recovery noted is likely due to reduced 
cryoprotectant exposure of cells in the centre of the clumps leading to cell 
death during slow freezing. 43   
 
Nonetheless, some studies have reported successful slow freezing of hESC 
colonies. 12,44-46  For instance, when freezing conditions were partially 
optimised (details of which can be found in the original report), an 
approximately 80% survival rate of the H1 hES cell line could be achieved. 45  
However, there was significant variation between runs (15%), indicating that 
benefits could be gained from further optimisation.  One of the critical factors 
in attaining high hESC survival identified in this study was the inclusion of an 
ice seeding step at -7 to -10°C. 45  Although more systematic studies are 
needed which explore the role of ice seeding, and other cryobiological factors, 
on slow freezing of hESCs, this is consistent with other studies. 15,47  
Furthermore, another study 46 has demonstrated the variability in cell survival 
between hES cell lines using a slow freezing method, highlighting that it is key 
to test any process on a number of lines with different provenances.  Notably 
though, Crook and colleagues 14 used a slow freezing technique to bank 6 
clinical grade hES cell lines.  Although the authors do not comment on the 
recovery of cells post-thaw as this was not the main focus of the work, 
relatively large numbers of cells were frozen in this manner: 40-60 straws with 
3x106 cells/straw (in 200 μl media), underlining the potential advantage of this 
technique over vitrification in terms of how many cells can be preserved at 
once.   
 
Ideally, in order to avoid potential mass transfer issues through cell clumps, 
hESCs would need to be frozen in a single cell suspension, as other 
mammalian cells frequently are.  However, hESCs are typically passaged and 
frozen as colonies because single cells are susceptible to dissociation-
induced apoptosis. 48  In fact, Richards and colleagues 16 speculated that the 
poor survival rates following conventional slow freezing of hESC clumps was 
due to ice crystal formation during the process disrupting cell adhesion. 
However, Watanabe et al. 48 demonstrated that dissociating cells in the 
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presence of a small molecule Rho-kinase inhibitor (Y27632) significantly 
improved cell survival by protecting cells against apoptosis.  More recently a 
number of different studies have shown that using this inhibitor in both the 
freezing and thawing media increased hESC survival rate, reduced recovery 
time and increased subsequent colony formation compared to controls when 
cells were dissociated to the single cell level. 43, 49-52  Although not specified in 
every study, 1-2x106 cells/cryocontainer were typically preserved in this 
manner. 50,52  A number of Rho-kinase inhibitors exist and continue to be 
tested for their effects on hESCs 53 and the mechanism of action of Y27632 is 
still debated. 43,48,54  Nonetheless, Y27632 is still the most commonly used 
anti-apoptotic agent at the moment.  It remains to be seen whether alternative 
compounds, such as caspase inhibitors, 55  become more widely used in the 
future.   
 
In addition to slow freezing hESCs in suspension, either as clumps or as 
single cells, cryopreservation of hESCs in situ on tissue culture plates, 56 
cassettes 57 and microcarriers 58 has recently been reported.  Cryopreserving 
hESCs embedded between two layers of the extracellular matrix substitute 
Matrigel on tissue culture plates, significantly increased the viability of 
colonies compared to those frozen in suspension and those preserved on a 
single layer of Matrigel. 56  Similarly, Amps et al. 57 showed poor survival and 
recovery of hESC colonies when cryopreserved in feeder cell layer coated T 
flasks.  However, these workers had greater success cryopreserving hESC 
colonies in tissue culture cassettes (Clinicell cassettes from Mabio 
International, France).  Following freezing and thawing more than 100 
colonies adhered, as compared with 0-3 colonies in the tissue culture flasks, 
and high levels of pluripotency markers were retained.   
 
Preserving cells in situ enables the maintenance of cell-cell connections and 
abolishes the need for certain processing steps such as dissociation of the 
cells from the surface, although it is not particularly scalable.  This is due to 
the cost of freezing medium to cover such large surface areas and the space 
required to store T flasks, plates or cassettes when compared with vials.  
Work also needs to be done to optimise the cooling rates achievable in such 
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systems but it nonetheless presents an interesting opportunity to generate 
frozen plates of assay ready cells for use in in vitro assays such as toxicology 
studies.     
 
The past five years or so has seen a number of studies developing methods 
for culturing hESCs on microcarriers. 59-66  These provide a much larger 
surface area to volume ratio for not only growth but, potentially, also 
cryopreservation.  Indeed, Nie et al. 58 demonstrated that preserving hESCs 
on the microcarriers they were grown on resulted in a higher recovery of 
undifferentiated cells compared to cells preserved in suspension.  
Microcarriers are available in a variety of porosities that can enable or restrict 
the penetration of cells into the carrier.  Notably, the microcarriers used by Nie 
and colleagues were microporous, meaning that cells only grew in colonies on 
the outer surface of the carrier and thus were not subject to any mass transfer 
issues such as nutrient or cryoprotectant diffusion.  Although they only 
preserved 106 cells/ml in cryovials, the number of cells preserved could 
hopefully be increased with some optimisation.  From a bioprocessing 
perspective, this is an interesting advance because it would reduce the 
number of processing steps, and hence, time.  The added advantage of this 
technique would also be that successful differentiation of hESC on 
microcarriers to endoderm 60 and cardiomyocytes 67 has been reported.  
Therefore cells could be grown, preserved, thawed and then differentiated on 
microcarriers, further cutting down on processing steps.   
 
Given the precedent with other mammalian cell lines such as the CHO-S used 
in the biopharmaceutical industry, 38 there is great potential for large numbers 
of hESCs to be cryopreserved at once through slow freezing.  However, this 
has yet to be reported and it remains to be seen whether it can be achieved 
whilst maintaining the key characteristics of these cells.  Notably, much of the 
work discussed here, including that on the use of ROCK inhibitors, has 
focussed on growth of hESCs in colonies.  However, single cell propagation 
and/or passaging would facilitate and improve not just cryopreservation but 
cell processing in general.  Work is ongoing in this area but it has already 
been reported that hESCs can be grown in monolayers 7-9 or aggregate 
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suspension, 68-71 with enzymatic treatment used to dissociate cells into small 
clumps.  Such small clumps should be more amenable to slow freezing, 
allowing large quantities of hESCs to be preserved at once, but little has been 
reported on the cryopreservation of cells grown in monolayer or suspension.  
For example, Priddle and colleagues 8 reported that a conventional slow 
freezing protocol, without the inclusion of a Rho-kinase inhibitor, was used to 
preserve cells grown in monolayers but there was no mention of post-thaw 
recovery rates.   
 
 
3.5  Cryopreservation of hESC-derived cells 
 
Current work on hESC differentiation into clinical and research relevant cells 
is generally focused on either the development of differentiation protocols or 
improving the efficiency of existing protocols.  However, some reports are 
emerging which look at whether hESC-derived cells can be cryopreserved 
using slow freezing or vitrification. 
 
For example, human ESC-derived neurons have been successfully 
cryopreserved using a slow freezing technique. 72  By exposing cells to a 
caspase inhibitor, which aims to prevent apoptosis, recovery rates of up to 
83% could be achieved.  Consistent with literature on hESCs, Norström et al. 
55 were able to successfully slow freeze single cell suspensions, but not 
clusters, of cardiomyocytes.  Clumps of cardiomyocytes could, however, be 
preserved by using a sealed straw vitrification method.  Unfortunately, in their 
article the authors did not specify what recovery rates were obtained.  Another 
study revealed that when during the differentiation protocol hESC-derived 
cardiomyocytes were cryopreserved had a significant impact on the recovery 
of cell function. 73  Furthermore, they also noted that the beating frequency of 
cardiomyocyte clusters post-thaw was higher than that of non frozen clusters, 
highlighting some of the physiological changes that may occur in cells as a 
result of cryopreservation.  It is clear that simple cell survival assays are not 
sufficient and that in depth analysis of cellular function post-thaw should be 
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carried out in all studies, particularly if these cells are to be used as 
therapeutic agents.  
 
Given the likely future impact of hESC-derived cells on healthcare as either 
cellular therapies themselves or in drug screening assays, it is particularly 
important that robust and consistent methods for preserving these cells are 
developed.  Again, the scalability of such methods will be critical, particularly 
as some reports emerge on the expansion of hESC-derived cells and not just 
the differentiation protocols themselves (for example 74,75).  Thus, it is 
promising to see that in a study using a mixed cell population which included 
25-59% hESC-derived cardiomyocytes, 4-8x107 cells per 1.5 ml cryovial could 
be preserved using a slow freezing protocol. 76  Recovery rates of ~75% were 
achieved, a promising indication that large scale preservation of hESC-
derived cells is feasible.  However, in light of some of the physiological 
changes in hESC-derived cardiomyocytes noted by Kim and colleagues post-
thaw, much optimisation of such protocols may still be needed.  It also 
remains to be seen whether hESC-derived cells can be frozen successfully in 
assay-ready plates in order to cut down on processing time if these cells are 
to be used in, for instance, toxicology studies. 
 
 
 
4. Dry preservation: a potential alternative to cryopreservation 
 
Whilst the use of slow freezing for the preservation of hESCs and their 
differentiated progeny shows the potential to be scalable, there are issues 
with this technique that are not related to scale and have therefore not been 
discussed here.  For example, although DMSO is commonly used as a 
cryoprotectant, even in GMP-compatible solutions such as CryoStor (BioLife 
Solutions Inc, WA, USA), it is toxic to cells 23,29 and can cause adverse 
reactions in patients. 77  Transport of vitrified cells can also be very expensive 
as dry shippers, which hold samples at -150°C without the risks associated 
with transporting liquid nitrogen, are required to prevent any partial thawing of 
the cells.  Thus, it is important to consider whether a preservation method, 
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such as dry preservation, which avoids the use of DMSO and results in a 
product that can be maintained at room temperature, would be suitable.   
 
Dehydrating cells in a controlled manner avoids low temperature storage 
altogether.  Generally, drying cells leads to membrane damage, protein 
denaturation and subsequent cell death but the natural ability of some 
organisms such as yeast cells and fungal spores to survive almost complete 
dehydration 78 suggests ‘safe’ dehydration and rehydration of mammalian 
cells should be possible.  If feasible this would be both economically and 
practically advantageous compared to cold storage and transport as dried 
formulations could be stored at room temperature, although care that 
conditions remain stable needs to be taken.  There is also a precedent, with 
lyophilisation of pharmaceutical-grade products occurring at a large scale, 
although its acceptance within the cell biology community may be more 
difficult.   
 
Freeze drying, or lyophilisation, is typically used to preserve bacterial cells 
and fungi and involves vacuum desiccation.  Briefly, there are three stages: 
freezing in order to partly crystallise the solvent so that it can be separated 
from the solutes, sublimation of the resultant ice (primary drying phase) and 
finally, a secondary drying phase where the majority of the remaining moisture 
is removed by desorption. 78  Cells can be pre-treated with a lyoprotectant 
such as disaccharide sugars but nonetheless, the process can be damaging. 
78,79    
 
Efforts to lyophilise mammalian cells have largely focused on trying to 
generate freeze-dried blood, with some studies showing that erythrocytes and 
platelets can be successfully lyophilised, stored and rehydrated, although the 
processes are not yet optimal. 78,80   Although the genomic material of mouse 
ES cells and spermatozoa has been preserved following freeze-drying, 81 it 
was not until recently that successful lyophilisation, storage for one week, and 
rehydration of nucleated cells was reported. 82  The authors demonstrated 
viability of mononuclear cells isolated from human umbilical cord blood 
following rehydration, with similar levels of CD34+ haematopoietic stem cells 
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present in the population before and after preservation, which were capable of 
differentiating into a number of cell types.  Although it remains to be seen 
whether lyophilised hESCs would retain their characteristics, this technique 
represents an interesting alternative to cryopreservation and should be 
explored.   
 
Cells can also simply be dried under vacuum for example, without the need 
for freezing.  As with lyophilisation, the introduction of a disaccharide such as 
trehalose, or a combination of trehalose and glycerol, into the cells offers 
protection from desiccation. 83  It has been shown that human mesenchymal 
stem cells exposed to trehalose and glycerol can be successfully dehydrated 
under vacuum and stored for 1 day. 84  Upon rehydration they regained their 
normal morphology and adhesive capability, were >90% viable, proliferated 
and maintained expression of key surface markers.  However, the authors did 
admit that there was a large amount of inconsistency from trial to trial and that 
longer storage times would need to be achieved, again underlining the need 
for these techniques to be improved and optimised.   
 
Furthermore, based on their findings in human foreskin fibroblasts, Puhlev 
and colleagues 83 suggested that free-radical mediated damage may occur 
within desiccated cells.  Thus there is a need for a variety of post-preservation 
assays to be carried out, beyond the simple viability tests to ascertain that 
cells have not been damaged or altered in any manner. This will be 
particularly true of hESCs and their derivatives if they are to be used in the 
clinic.     
 
Notably, one the biggest hurdles to successful lyophilisation or dehydration of 
cells is delivering the protective agents, such as the disaccharide trehalose, 
into cells as both their intracellular and extracellular presence is required for 
maximum effect.  Trehalose is a hydrophilic compound and therefore non-
permeating but an intracellular concentration of ≥100mM is required for 
effective cell protection. 85,86  A number of different techniques have been 
used to deliver trehalose into cells including thermal shock, 83 induction of 
trehalose synthesis in cells by genetic engineering 87 and induction of pore 
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formation using mutant bacterial toxins. 88   However, these techniques 
typically do not achieve a high enough intracellular concentration of trehalose, 
can be cytotoxic and/or represent safety concerns if the treated cells are 
subsequently to be used as therapies.  Novel cell loading techniques are 
therefore being developed.  For instance, unilamellar liposomes containing 
trehalose have been used to deliver this disaccharide into erythrocytes.  
Transfer of trehalose is believed to occur through both adsorption of the lipid 
vesicles to the erythrocyte membrane and also membrane fusion. 89  The 
generation of trehalose-containing, thermally-responsive, nanocapsules has 
enabled up to 300mM trehalose to be loaded into 3T3 fibroblasts through 
absorptive endocytosis. 86   However, a cold shock step was used to release 
trehalose from the nanocapsules intracellularly and it remains to be seen how 
hESCs would be affected by such treatment.  Another approach has been to 
use a biopolymer (poly(L-lysine iso-phtalamide) backbone with L-
phenylalanine attached) to increase membrane permeability of cells to 
trehalose. 85  The authors reported a significant increase in trehalose loaded 
into erythrocytes using this biopolymer, when compared to cells treated with 
poly(L-lysine iso-phtalamide) and trehalose or trehalose alone.      
 
Overall, this work is encouraging and suggests that although much work 
would need to be done to optimise protocols for use with hESCs or hESC-
derived cells, dry preservation represents a potential alternative for hESC 
preservation.  It would be a particularly attractive option for longer-term 
banking.   
 
 
5. Conclusions 
 
The recent start of some long-awaited clinical trials using hESC-derived cells 
in both the UK and USA highlights the potential use of these cells as 
therapeutic agents.  Furthermore, as methods by which to produce these cells 
reproducibly at scale continue to be developed, their use in drug screening 
and toxicology assays is also set to increase.  With 106-109 cells typically 
being required per patient 13 and an even larger number of cells required for a 
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single HTS campaign, 5 it is important that scalable techniques to preserve 
these cells and hESCs themselves are developed.  Currently, hESCs and 
their differentiated progeny are either vitrified or preserved by slow freezing: 
cryopreserved hESCs can be obtained from cell banks, cryopreserved hESC-
derived cardiomyocytes are available commercially for use in in vitro assays 
and Geron’s hESC-derived oligodendrocyte progenitor cells (GRNOPC1), 
which are currently undergoing clinical trials, are also supplied as a 
cryopreserved formulation.   
 
Although vitrification of hESCs can lead to high cell recovery rates, it remains 
an inefficient process, requires a skilled operator and can only preserve very 
small quantities of cells.  Unfortunately, because of the inherent nature of 
vitrification, true scale-up is not an option.  Process automation would relieve 
some of the burden, allowing larger numbers of cryocontainers to be 
processed, but would not overcome the inherent problem that each container 
can only hold limited volumes.   
 
Mixed results using slow freezing to preserve hESCs have been reported.  
However, this method is much more scalable than vitrification, as shown by 
the ability to preserve large numbers of, for example, CHO-S cells. 38  Slow 
freezing is also more suited to preservation of cells in single cell suspension 
than in colonies, which is compatible with recent developments in hESC 
culture processes.  However, whether hESCs grown in monolayers or 
suspension cultures can be successfully cryopreserved (with or without the 
use of ROCK inhibitors), has yet to be published.   
 
Although optimisation for use with hESCs and their differentiated progeny is 
undoubtedly required to retain maximum cell function, be GMP compliant and 
so forth, the scalability of slow freezing protocols means that it is likely to 
become the cryopreservation method of choice in the coming years.  It will 
allow large numbers of cells to be frozen and stored at once if existing 
technologies such as cryobags and bag handling systems are exploited.  
Nonetheless, as highlighted in this review, alternatives to cryopreservation, 
such as lyophilisation, do exist and should also be explored.   
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Figure 1. Stages during the culture process when hESCs or their derived progeny may be preserved.  A schematic 
to show sequential expansion and banking of cells.  A master cell bank (MCB) could contain ≤400 cryovials, each preserving 
≤107 cells. 79  One vial of the MCB would be used to generate the subsequent working cell bank (WCB).  Notably, hESC-
derived cells could also be expanded prior to being preserved or utilised but this has been omitted for clarity. 
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DIFFERENTIATION 
DIFFERENTIATION 
WCB 
Figure 2. Schematic of the key stresses incurred by cells during freezing. If sufficiently high cooling rates can be 
attained vitrification may be achieved (not shown).  Notably, spontaneous formation of extracellular ice can only occur when 
the extracellular solution is cooled below its equilibrium melting point (e.g. ~ - 10°C).  During slow freezing protocols, when 
extracellular ice formation is encouraged, ice is commonly deliberately seeded at -1 to -5°C by touching the sample with a 
pre-chilled needle.  This manual seeding avoids additional cell damage which can be caused by the spontaneous formation 
of ice crystals in supercooled solutions. 22-26  Based on Figure 1 from 24.   
SLOW 
RAPID 
VERY  
RAPID 
Ice crystals 
Flow of water  
• Water continues to be 
drawn out of the cell, 
causing shrinkage. 
• The osmotic imbalance 
may be severe enough to 
concentrate intracellular 
solutes to toxic levels.  
Intracellular ice forms 
because insufficient 
dehydration has occurred. 
Intracellular ice crystals 
may form but are too 
small and too few to 
cause damage. 
Formation of extracellular ice 
leads to creation of an osmotic 
imbalance, drawing water out 
of the cell. 
< -10°C 
Figure 3. Outline of typical processing steps in conventional slow freezing and vitrification.  Cells are first harvested 
from their culture environment.  As hESCs are adherent, this involves either a mechanical or enzymatic dissociation step into 
either clumps or single cell suspensions.  Slow freezing: cells are usually exposed to the cryopreservation medium containing 
CPA(s) and quickly transferred into cryocontainers (e.g. 1 ml cryovial), although stepwise addition of CPAs is sometimes 
done. Manual ice seeding is typically carried out before vials are then cooled at a controlled rate to at least -80°C.  These are 
subsequently stored long term in the vapour phase of liquid nitrogen.  Following rapid thawing, cells are transferred into pre-
warmed growth medium in order to dilute out the CPA(s).  Vitrification:  ~5 clumps of cells are manually transferred through at 
least two vitrification solutions containing CPA(s) before being placed in a cryocontainer (e.g. a cryostraw) and plunged 
directly into liquid nitrogen.  Stepwise exposure to CPAs is used to avoid osmotic stress and toxicity.  Rapid thawing is 
achieved by plunging the vitrified cells directly into pre-warmed media, although again several thawing media are used to 
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Figure 4.  Outline of the OPS method of vitrification commonly used to preserve hESCs grown in colonies. Colonies 
of cells are first dissected into smaller clumps before being processed as shown. Based on the methods detailed in 12,35. 
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